Antiprogestins, a New Form of Endocrine Therapy for Human Breast Cancer

Cancer Research

Volumn 49, Issue 11, 1989, Pages 2851-2856

  Klijn, Jan G M ^a   Bakker, Ger H ^a   Rodenburg, Cees J ^a   Alexieva Figusch, Jana ^a   de Jong, Frank H ^b   Lamberts, Steven W J ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; DEXAMETHASONE;

ANOREXIA; BREAST CANCER; CLINICAL ARTICLE; FATIGUE; FEMALE; HORMONAL THERAPY; HUMAN; NAUSEA; PRIORITY JOURNAL; SOMNOLENCE; VERTIGO;

AGED; ANDROSTENEDIONE; BREAST NEOPLASMS; DRUG EVALUATION; ESTRADIOL; ESTRENES; FEMALE; HUMAN; HYDROCORTISONE; LYMPHATIC METASTASIS; MIDDLE AGE; MIFEPRISTONE; SUPPORT, NON-U.S. GOV'T;

EID: 0024319047     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Philibert, D., Deraedt, R., Teutsch, G., Tourneminen, C., and Sakiz, E. RU 38486—a new lead for steroidal antihormones. In Proceedings of the 64th Annual Endocrine Society Meeting, San Francisco, Abstract 668, 1982.
2. Herrmann, W., Wyss, R., Riondel, A., Philibert, D., Teutsch, G., Sakiz, E., and Baulieu, E. E. The effect of an antiprogesterone steroid on women: interruption of the menstrual cycle and of early pregnancy. CR. Hebd. Seances Acad. Sci., 284:933–937, 1982.
3. Healy, D. L., Baulieu, E. E., and Hogden, C. G. Induction of menstruation by an antiprogesterone steroid (RU 486) in primates: site of action, dose-response relationships, and hormonal effects. Fertil. Steril., 40: 253–257, 1983.
4. Schaison, G., George, M., Lestrat, N., Reinberg, A., and Baulieu, E. E. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women. J. Clin. Endocrinol. Metab., 61:484–489, 1985.
5. Tseng, L., Marella, J., and Sun, B. Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen, and RU 486. Endocrinology, 118:1312–1318, 1986.
6. Croxatto, H. B., Salvatierra, A. M., Romero, C., and Spitz, I. M. Late luteal phase administration of RU 486 for three successive cycles does not disrupt bleeding patterns or ovulation. J. Clin. Endocrinol. Metab., 65:1272–1277, 1987.
7. Liu, J. H., Garzo, V. G., Morris, S., Stuenkel, C., Uhlmann, A., and Yen, S. S. C. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. J. Clin. Endocrinol. Metab., 65: 1135–1139, 1987.
8. Garzo, V. G., Liu, J. H., Uhlmann, A., Baulieu, E. E., and Yen, S. S. C. Effects of an antiprogesterone (RU 486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle. J. Clin. Endocrinol. Metab., 66:508–517, 1988.
9. Gravanis, A., Schaison, G., George, M., de Brux, J., Satyaswaroop, P. G., Baulieu, E. E., and Robel, P. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J. Clin. Endocrinol. Metab., 60:156–163, 1985.
10. Collins, R. L., and Hodgen, G. D. Blockade of the spontaneous midcycle gonadotropin surge in monkeys by RU 486: a progesterone antagonist or agonist? J. Clin. Endocrinol. Metab., 63:1270–1276, 1986.
11. Horwitz, K. B. The antiprogestin RU 38486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-sensitive T47D10 human breast cancer cells. Endocrinology, 116:2236–2245, 1985.
12. Philibert, D., Deraedt, R., and Teutsch, G. RU 38486, a potent antigluco-corticoid in vivo. In: Proceedings of the 8th International Congress of Pharmacology, Tokyo, Abstract 1463, p. 668. Japanese Pharmacological Society and Science Council of Japan, 1981.
13. Chobert, M. N., Barouki, R., Finidori, J., Aggerbeck, M., Hanoune, J., Philibert, D., and Deraedt, R. Antiglucocorticoid properties of RU 38486 in a differentiated hepatoma cell line. Biochem. Pharmacol., 32: 3481–3483, 1983.
14. Healy, D. L., Chrousos, G. P., Schulte, H. M., Williams, R. F., Gold, P. W., Baulieu, E. E., and Hodgen, G. D. Pituitary and adrenal responses to the antiprogesterone and antiglucocorticoid steroid RU 486 in primates. J. Clin. Endocrinol. Metab., 57:863–865, 1983.
15. Moguilewsky, M., and Philibert, D. RU 38486: potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J. Steroid. Biochem., 20:271–276, 1984.
16. Bertagna, X., Bertagna, C., Luton, J.-P., Husson, J.-M., and Girard, F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J. Clin. Endocrinol. Metab., 59:25–28, 1984.
17. Healy, D. L., Chrousos, G. P., Schulte, H. M., Gold, P. W., and Hodgen, G. D. Increased adrenocorticotropin, Cortisol, and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: dose response relationships. J. Clin. Endocrinol. Metab., 60:1–4, 1985.
18. Gaillard, R. C., Poffet, D., Riondel, A. M., and Saurat, J.-H. Ru 486 inhibits peripheral effects of glucocorticoids in humans. J. Clin. Endocrinol. Metab., 67:1009–1011, 1985.
19. Lamberts, S. W. J., Bons, E. G., and Uitterlinden, P. Studies on the glucocorticoid-receptor blocking action of RU 38486 in cultures ACTH-secreting human pituitary tumour cells and normal rat pituitary cells. Acta Endocrinol., 109:64–69, 1985.
20. Gagne, D., Pous, M., and Philibert, D. RU 38486: a potent antiglucocorticoid in vitro and fit vivo. J. Steroid Biochem., 23:247–251, 1985.
21. Chasserot-Golaz, S., and Beck, G. Metabolism and antiproliferative effect of the glucocorticoid antagonist RU 38486 in cultured liver and hepatoma cells. J. Steroid Biochem., 24:423–426, 1986.
22. Couzinet, B., Le Strat, N., Uhlmann, A., Baulieu, E. E., and Schaison, G. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). N. Engl. J. Med., 575; 1565–1570, 1986.
23. Das, C., and Catt, K. J. Antifertility actions of the progesterone antagonist RU 486 include direct inhibition of placental hormone secretion. Lancet, 2: 599–601, 1987.
24. Palca, J. Abortion-inducing drug alarms the right-to-life lobby. Nature (Lond.), 325:185, 1987.
25. Nieman, L. K., Chrousos, G. P., Keiner, C., Spitz, I. M., Nisula, B. C., Cutler, G. B., Merriam, G. R., Bardin, C. W., and Loriaux, D. L. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab., 61:536–540, 1985.
26. Bertagna, X., Bertagna, C., Laudat, M.-H., Husson, J.-M., Girard, F., and Luton, J.-P. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J. Clin. Endocrinol. Metab., 63:639–643, 1986.
27. Contreras, P., Caviedes, R., Rojas, A., and Lopez, M. Adrenal cancer tumor regression with ketoconazole or mifepristone (RU 486). In vivo and in vitro evidence supporting tumoral hormone-dependency. In: Proceedings of the 69th Annual Endocrine Society Meeting, Indianapolis, Abstract 8, p. 23, 1987.
28. Phillips, C. I., Gore, S. M., Green, K., Cullen, P. M., and Campbell, M. Eye drops of RU 486–6, a peripheral steroid blocker, lower intraocular pressure in rabbits. Lancet, 7:767–768, 1984.
29. Chalbos, D., and Rochefort, H. Dual effects of the progestin R 5020 on proteins released by the T47D human breast cancer cells. J. Biol. Chem., 259:1231–1238, 1984.
30. Bardon, S., Vignon, F., Chalbos, D., and Rochefort, H. RU 486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J. Clin. Endocrinol. Metab., 50:692–697, 1985.
31. Bardon, S., Vignon, F., Mountcourrier, P., and Rochefort, H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res., 47:1441–1448, 1987.
32. Gill, P. G., Vignon, F., Bardon, S., Derocq, D., and Rochefort, H. Difference between R 5020 and the antiprogestin RU 486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res. Treat., 10:37–45, 1987.
33. Bakker, G. H., Setyono-Han, B., Henkelman, M. S., de Jong, F. H., Lamberts, S. W. J., van der Schoot, P., and Klijn, J. G. M. Comparison of the actions of the antiprogestin mifepristone (RU 486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep., 71:1021–1027, 1987.
34. Bakker, G. H., Setyono-Han, B., de Jong, F. H., and Klijn, J. G. M. Mifepristone in treatment of experimental breast cancer in rats. In: J. G. M. Klijn, R. Paridaens, and J. A. Foekens (eds.), Hormonal Manipulation of Cancer Peptides, Growth Factors, and New (Anti)steroidal agents, EORTC Monograph Series, Vol. 18, pp. 39–46. New York: Raven Press, 1987.
35. Lamberts, S. W. J., Uitterlinden, P., Bons, E. G., and Verleun, T. Comparison of the actions of RU 38486 and megestrol acetate in the model of a transplantable adrenocorticotropin- and prolactin-secreting rat pituitary tumor. Cancer Res., 45:1015–1019, 1985.
36. Lamberts, S. W. J., van Koetsveld, P., and Verleun, T. Prolactin release-inhibitory effects of progesterone, megestrol acetate, and mifepristone (RU 38486) by cultured rat pituitary tumor cells. Cancer Res., 47: 3667–3671, 1987.
37. Blankenstein, M. A., van de Meulen-Dijk, C., van’t Verlaat, J. W., Blaauw, G., and Thyssen, J. H. H. Progestin receptors in human meningioma cells in culture. In Proceedings of the 69th Annual Endocrine Society Meeting, Indianapolis, Abstract 190, p. 68, 1987.
38. Klijn, J. G. M., Lamberts, S. W. J., de Jong, F. H., Docter, R., van Dongen, K. J., and Birkenhager, J. C. The importance of pituitary tumour size in patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension of tumour. Clin. Endocrinol., 12:341–355, 1980.
39. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer, 16:1513–1515, 1980.
40. Setyono-Han, B., Henkelman, M. S., Foekens, J. A., and Klijn, J. G. M. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res., 47:1566–1570, 1987.
41. Romieu, G., Maudelonde, T., Uhlmann, A., Pujol, H., Grenier, J., Cavalie, G., Khalaf, S., and Rochefort, H. The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trial. Bull. Cancer, 74:455–461, 1987.
42. Klijn, J. G. M., de Jong, F. H., Lamberts, S. W. J., and Alexieva-Figusch, J. Antiprogestin (RU 486) treatment of postmenopausal metastatic breast cancer. In: Proceedings of the 8th International Congress of Endocrinology, Kyoto, Abstract 16–19–133, p. 434, 1988.
43. Labrie, F., Poulin, R., Simard, J., Hubert, J.-F., Spinola, P., and Marchetti, B. Adrenal steroids exert potent estrogenic action in both normal and cancer tissue. In: J. G. M. Klijn, R. Paridaens, and J. A. Foekens (eds.), Hormonal Manipulation of Cancer Peptides, Growth Factors, and New (Anti)steroidal Agents, EORTC Monograph Series, Vol. 18, pp. 7–17. New York: Raven Press, 1987.
44. Dauvois, S., and Labrie, F. Androstenedione is a potent stimulus for the growth of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. In: Proceedings of the 8th International Congress of Endocrinology, Kyoto, Abstract 13–18–068, p. 359, 1988.
45. Lamberts, S. W. J., Polderman, D., Zweens, M., and de Jong, F. H. Familial Cortisol resistance: differential diagnostic and therapeutic aspects. J. Clin. Endocrinol. Metab., 63:1328–1333, 1986.
46. Wade, C. E., Spitz, I. M., Lahteenmaki, P., Heikinheimo, O., Krieger, D. T., and Bardin, C. W. Effects of the antiglucocorticoid RU 486 on adrenal function in dogs. J. Clin. Endocrinol. Metab., 66:473–479, 1988.